(VIANEWS) – Salesforce (CRM), Zebra Technologies (ZBRA), Alexion Pharmaceuticals (ALXN) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Salesforce (CRM)

23.9% sales growth and 11.52% return on equity

salesforce.com, inc.

Salesforce’s sales growth this year is anticipated to be 23.8% and 19.6% for next year.

Year-on-year quarterly revenue growth grew by 22.6%, now sitting on 22.35B for the twelve trailing months.

Volume

Today’s last reported volume for Salesforce is 5197190 which is 10.9% below its average volume of 5833530.

Salesforce’s sales growth is a negative 0% for the present quarter and 23.9% for the next. The company’s growth estimates for the present quarter and the next is a negative 47.1% and negative -23.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.52%.

Volatility

Salesforce’s last day, last week, and last month’s current intraday variation average was 2.29%, 2.55%, and 1.71%, respectively.

Salesforce’s highest amplitude of average volatility was 2.41% (day), 3.69% (last week), and 3.01% (last month), respectively.

Salesforce’s Stock Yearly Top and Bottom Value

Salesforce’s stock is valued at $226.06 at 00:22 EST, way under its 52-week high of $311.75 and way higher than its 52-week low of $201.51.

Salesforce’s Moving Average

Salesforce’s value is way below its 50-day moving average of $287.70 and way under its 200-day moving average of $254.07.

Previous days news about Salesforce(CRM)

  • According to VentureBeat on Tuesday, 18 January, "Lerhaupt was a VP of engineering at RelateIQ, which Salesforce acquired in 2014. ", "Martin and Grinolds were also software engineers at RelateIQ and stayed on after the Salesforce acquisition."
  • According to VentureBeat on Tuesday, 18 January, "Even before the pandemic, according to sales leaders, AI adoption in sales was expected to grow by 155% in 2020, according to a 2018 Salesforce report."

2. Zebra Technologies (ZBRA)

7.8% sales growth and 35.6% return on equity

Zebra Technologies Corporation, together with its subsidiaries, provides enterprise asset intelligence solutions in the automatic identification and data capture solutions industry worldwide.

Zebra Technologies’s sales growth this year is anticipated to be 24.5% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 26.9%, now sitting on 5.47B for the twelve trailing months.

Volume

Today’s last reported volume for Zebra Technologies is 330782 which is 21.18% above its average volume of 272961.

Zebra Technologies’s sales growth for the next quarter is 7.8%. The company’s growth estimates for the present quarter and the next is 24.2% and negative -6.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.6%.

Volatility

Zebra Technologies’s last day, last week, and last month’s current intraday variation average was 2.18%, 1.12%, and 1.29%, respectively.

Zebra Technologies’s highest amplitude of average volatility was 1.55% (day), 2.98% (last week), and 2.56% (last month), respectively.

Zebra Technologies’s Stock Yearly Top and Bottom Value

Zebra Technologies’s stock is valued at $516.72 at 00:22 EST, way under its 52-week high of $615.00 and way above its 52-week low of $363.00.

Zebra Technologies’s Moving Average

Zebra Technologies’s value is under its 50-day moving average of $562.85 and under its 200-day moving average of $531.45.

3. Alexion Pharmaceuticals (ALXN)

7.4% sales growth and 4.43% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals’s sales growth this year is expected to be 10.6% and 7% for next year.

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 6.26B for the twelve trailing months.

Alexion Pharmaceuticals’s sales growth for the next quarter is 7.4%. The company’s growth estimates for the current quarter and the next is 7.1% and 4.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.43%.

Alexion Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals’s stock is valued at $0.00 at 00:22 EST, below its 52-week low of $99.91.

Alexion Pharmaceuticals’s Moving Average

Alexion Pharmaceuticals’s worth is under its 50-day moving average of $182.75 and below its 200-day moving average of $165.77.

4. Akamai Technologies (AKAM)

5.7% sales growth and 13.94% return on equity

Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing content and business applications over the Internet in the United States and internationally.

Akamai Technologies’s sales growth this year is expected to be 7.6% and 7.6% for next year.

Year-on-year quarterly revenue growth grew by 7.3%, now sitting on 3.33B for the twelve trailing months.

Volume

Today’s last reported volume for Akamai Technologies is 1464890 which is 11.68% above its average volume of 1311580.

Akamai Technologies’s sales growth for the next quarter is 5.7%. The company’s growth estimates for the current quarter and the next is 6.1% and 7.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.94%.

Volatility

Akamai Technologies’s last day, last week, and last month’s current intraday variation average was 0.48%, 0.62%, and 0.76%, respectively.

Akamai Technologies’s highest amplitude of average volatility was 1.37% (day), 1.93% (last week), and 1.62% (last month), respectively.

Akamai Technologies’s Stock Yearly Top and Bottom Value

Akamai Technologies’s stock is valued at $112.08 at 00:22 EST, way under its 52-week high of $124.91 and way above its 52-week low of $92.64.

Akamai Technologies’s Moving Average

Akamai Technologies’s value is above its 50-day moving average of $108.19 and higher than its 200-day moving average of $110.08.

5. Brixmor Property Group (BRX)

5.2% sales growth and 4.26% return on equity

Brixmor (NYSE: BRX) is a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers.

Brixmor Property Group’s sales growth this year is anticipated to be 6.6% and 2.7% for next year.

Year-on-year quarterly revenue growth declined by 0.9%, now sitting on 1.05B for the twelve trailing months.

Volume

Today’s last reported volume for Brixmor Property Group is 397936 which is 81.87% below its average volume of 2194960.

Brixmor Property Group’s sales growth is a negative 0% for the ongoing quarter and 5.2% for the next. The company’s growth estimates for the present quarter and the next is 66.7% and 100%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.26%.

Volatility

Brixmor Property Group’s last day, last week, and last month’s current intraday variation average was 0.96%, 0.76%, and 1.61%, respectively.

Brixmor Property Group’s highest amplitude of average volatility was 1.80% (day), 1.77% (last week), and 2.74% (last month), respectively.

Brixmor Property Group’s Stock Yearly Top and Bottom Value

Brixmor Property Group’s stock is valued at $24.40 at 00:22 EST, below its 52-week high of $25.83 and way higher than its 52-week low of $15.55.

Brixmor Property Group’s Moving Average

Brixmor Property Group’s value is higher than its 50-day moving average of $24.14 and above its 200-day moving average of $22.91.

LEAVE A REPLY

Please enter your comment!
Please enter your name here